Is MOTS-c Legal in Texas? How to Access It Legally

HealthRX.com

No federal pathway makes MOTS-c clearly legal in Texas

Print or save as PDF

See the public record for MOTS-c

  • FDA status / Not an approved drug and not a component of one [1]
  • Compounding lists / In none of the three categories for state-licensed pharmacies; absent from the outsourcing-facility list [2][6][3]
  • Advisory vote / July 23, 2026 vote favored listing; advice only, not binding [7][4]
  • Draft HHS policy / Nonbinding; MOTS-c acetate by injection only, if conditions are met [4][5]
  • Human data / FDA found no published study giving MOTS-c to a person [1]
  • Sport / WADA prohibits it at all times under S4.4.1 [8]

Is MOTS-c approved or on FDA's compounding lists?

No. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, first reported in 2015 [9]. It is not an FDA-approved drug and is not a component of one; FDA's July 2026 review found no USP or National Formulary monograph, no European or Japanese pharmacopeia listing and no product authorized by the European Medicines Agency [1]. The free base and the acetate salt are treated as different bulk substances [1].

For state-licensed physicians and pharmacies, FDA describes three ways a bulk substance can qualify for compounding: an applicable USP or National Formulary monograph, use as a component of an FDA-approved drug, or inclusion on FDA's bulks list [3]. MOTS-c meets none of those. It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) and is absent from the outsourcing-facility list (updated March 21, 2025), so FDA's category 1 policy does not cover it [2][6][3].

FDA's page on bulk substances that may present significant safety risks (content dated 04/22/2026) places MOTS-c in the nominated-but-withdrawn table. FDA says it has not identified human exposure data on MOTS-c given by any route and lacks important information about its safety. Removal from category 2 was not a finding that it is safe [10].

What would the draft HHS policy do?

HHS filed a draft enforcement-discretion policy on October 28, 2026 (Federal Register document 2026-22192) naming MOTS-c among six peptides and covering MOTS-c acetate by subcutaneous or intramuscular injection [4][5]. It says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with it if conditions are met. Those conditions include a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and a label reading 'This is a compounded drug product. Not for resale.' [4][5]. The notice says it does not establish any rights for any person, is not binding on HHS or the public, and may be revisited, for example after a safety signal or product quality issue [4].

FDA's Pharmacy Compounding Advisory Committee voted on July 23, 2026 in favor of adding MOTS-c to the bulks list, against FDA staff's recommendation. That vote is advice only; MOTS-c is not on the list, and adding it takes formal rulemaking [7][4].

Does the federal position settle Texas access?

No. Texas law is separate, and none of the federal documents says Texas permits prescribing or compounding MOTS-c. Federally, MOTS-c is absent from FDA's compounding lists, and the draft policy describes only conditional, nonbinding enforcement discretion for the acetate injection [2][3][4][5]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [4].

FDA found no published study in which MOTS-c was given to a human; human studies measured the body's own MOTS-c, including after exercise [1][11][12]. WADA names MOTS-c in S4.4.1 (AMPK activators) and prohibits it at all times, in and out of competition, on the 2026 and 2027 Lists [8][13].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. According to the article, what is MOTS-c's status under FDA?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Questions worth asking

Choose the questions you want to keep

Is MOTS-c legal in Texas?
MOTS-c is not an approved drug and is absent from FDA's compounding lists [2][3]. The draft HHS policy sets out conditional, nonbinding federal enforcement discretion for MOTS-c acetate injections and states that it establishes no rights for any person. It does not address Texas law [4].
Can a Texas pharmacy compound MOTS-c?
MOTS-c is in none of the three categories on FDA's list for state-licensed pharmacies (updated May 14, 2026) and absent from the outsourcing-facility list (updated March 21, 2025) [2][6][3]. The draft policy covers only the acetate form by subcutaneous or intramuscular injection, and only if its conditions are met, including a patient-specific prescription and a certificate of analysis from an FDA-registered manufacturer [4][5].
Did the July 2026 advisory vote change that?
No. The committee voted on July 23, 2026 in favor of adding MOTS-c to the bulks list against staff's recommendation. The advice is not binding, MOTS-c is not on the list, and listing takes formal rulemaking [7][4].
Is MOTS-c safe?
Its safety in people is unknown. FDA found no human exposure data and no animal toxicity studies, and its stated concern for injection is immunogenicity from aggregation and peptide-related impurities [1][10].
Show all 13 referencesHide references
  1. U.S. Food and Drug Administration.
  2. U.S. Food and Drug Administration.
  3. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act | FDA.
  4. Official web page.
  5. Official web page.
  6. U.S. Food and Drug Administration.
  7. U.S. Food and Drug Administration.
  8. World Anti-Doping Agency.
  9. Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
  10. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  11. Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
  12. von Walden F, Fernandez-Gonzalo R, Norrbom J, Emanuelsson EB, Figueiredo VC, Gidlund EK, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3):1035-1042.
  13. World Anti-Doping Agency.
Evidence overview for Is MOTS-c Legal in Texas? How to Access It Legally